Jonathan Black
YOU?
Author Swipe
View article: Modal Analysis of Self-Deployable Tape Spring Booms: A Reverse Engineering Approach
Modal Analysis of Self-Deployable Tape Spring Booms: A Reverse Engineering Approach Open
Extendable booms for deploying payloads, solar sails, and antennas are promising, but developing a correlated modal analysis model of these sensitive systems using conventional methods remains challenging. To address this issue, we have ta…
View article: Implementing TD3 to train a Neural Network to fly a Quadcopter through an FPV Gate
Implementing TD3 to train a Neural Network to fly a Quadcopter through an FPV Gate Open
Deep Reinforcement learning has shown to be a powerful tool for developing policies in environments where an optimal solution is unclear. In this paper, we attempt to apply Twin Delayed Deep Deterministic Policy Gradients to train a neural…
View article: A Lattice-based Method for Optimization in Continuous Spaces with Genetic Algorithms
A Lattice-based Method for Optimization in Continuous Spaces with Genetic Algorithms Open
This work presents a novel lattice-based methodology for incorporating multidimensional constraints into continuous decision variables within a genetic algorithm (GA) framework. The proposed approach consolidates established transcription …
View article: Data from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i>
Data from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i> Open
HER2/neu gene amplification and PIK3CA driver mutations are common in uterine serous carcinoma (USC) and may represent ideal therapeutic targets against this aggressive variant of endometrial cancer. We examined the sensitivity to neratini…
View article: Supplementary Figure 2 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
Supplementary Figure 2 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression Open
Exposure of all nine cell lines to scalar concentrations of ADC for a total of 6 days. IC50 dose response curves of SYD985, T-DM1 and ADC isotype control in all 9 primary USC cell lines with differential HER2 expression tested in vitro (i.…
View article: Supplementary Figure 2 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
Supplementary Figure 2 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression Open
Exposure of all nine cell lines to scalar concentrations of ADC for a total of 6 days. IC50 dose response curves of SYD985, T-DM1 and ADC isotype control in all 9 primary USC cell lines with differential HER2 expression tested in vitro (i.…
View article: Supplementary Table 1 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
Supplementary Table 1 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression Open
Cathepsin B expression. Expression of CTSB vs GAPDH in the primary USC cell lines used for in in vitro validation experiments.
View article: Data from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
Data from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression Open
Uterine serous carcinoma (USC) is an aggressive form of endometrial cancer. Up to 35% of USC may overexpress the HER2/neu oncogene at strong (i.e., 3+) levels by IHC while an additional 40% to 50% express HER2/neu at moderate (2+) or low (…
View article: Supplementary Table 1 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
Supplementary Table 1 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression Open
Cathepsin B expression. Expression of CTSB vs GAPDH in the primary USC cell lines used for in in vitro validation experiments.
View article: Supplementary Figure S1 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure S1 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i> Open
Graph showing IC50 values for USPC-ARK-1 cell line after 72 hrs exposure to increasing concentration of neratinib.
View article: Data from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
Data from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression Open
Uterine serous carcinoma (USC) is an aggressive form of endometrial cancer. Up to 35% of USC may overexpress the HER2/neu oncogene at strong (i.e., 3+) levels by IHC while an additional 40% to 50% express HER2/neu at moderate (2+) or low (…
View article: Supplementary Figure S4 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure S4 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i> Open
Variation in body weight of the mice treated with neratinib (40 mg\kg), taselisib (10 mg\kg) and the combination of the two inhibitors. The arrows denote the time point in which we started the combination treatment in single agent resistan…
View article: Supplementary Figure 1 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
Supplementary Figure 1 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression Open
Exposure of all nine cell lines to scalar concentrations of ADC for a total of 3 days. IC50 dose response curves of SYD985, T-DM1 and ADC isotype control in all 9 primary USC cell lines with differential HER2 expression tested in vitro (i.…
View article: Supplementary Figure S3 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure S3 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i> Open
Cell proliferation assay of USPC-ARK-1 cells exposed for 2 weeks as described in the method section to taselisib (A, upper panel) or neratinib (B, lower panel) and treated thereafter with neratinib, taselisib and the combination of both ag…
View article: Supplementary Figure S1 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure S1 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i> Open
Graph showing IC50 values for USPC-ARK-1 cell line after 72 hrs exposure to increasing concentration of neratinib.
View article: Data from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i>
Data from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i> Open
HER2/neu gene amplification and PIK3CA driver mutations are common in uterine serous carcinoma (USC) and may represent ideal therapeutic targets against this aggressive variant of endometrial cancer. We examined the sensitivity to neratini…
View article: Supplementary Figure 1 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
Supplementary Figure 1 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression Open
Exposure of all nine cell lines to scalar concentrations of ADC for a total of 3 days. IC50 dose response curves of SYD985, T-DM1 and ADC isotype control in all 9 primary USC cell lines with differential HER2 expression tested in vitro (i.…
View article: Supplementary Figure S2 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure S2 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i> Open
Effect on pS6 in uterine serous carcinoma cells lines after exposure to neratinib, taselisib and the combination of both at the indicated concentration in a representative FISH+\PIK3CA mutated USC cell line (USPC-ARK-1) and in a representa…
View article: Supplementary Figure S3 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure S3 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i> Open
Cell proliferation assay of USPC-ARK-1 cells exposed for 2 weeks as described in the method section to taselisib (A, upper panel) or neratinib (B, lower panel) and treated thereafter with neratinib, taselisib and the combination of both ag…
View article: Supplementary Figure S2 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure S2 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i> Open
Effect on pS6 in uterine serous carcinoma cells lines after exposure to neratinib, taselisib and the combination of both at the indicated concentration in a representative FISH+\PIK3CA mutated USC cell line (USPC-ARK-1) and in a representa…
View article: Supplementary Figure S4 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure S4 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i> Open
Variation in body weight of the mice treated with neratinib (40 mg\kg), taselisib (10 mg\kg) and the combination of the two inhibitors. The arrows denote the time point in which we started the combination treatment in single agent resistan…
View article: SpaceDrones 2.0—Hardware-in-the-Loop Simulation and Validation for Orbital and Deep Space Computer Vision and Machine Learning Tasking Using Free-Flying Drone Platforms
SpaceDrones 2.0—Hardware-in-the-Loop Simulation and Validation for Orbital and Deep Space Computer Vision and Machine Learning Tasking Using Free-Flying Drone Platforms Open
The proliferation of reusable space vehicles has fundamentally changed how assets are injected into the low earth orbit and beyond, increasing both the reliability and frequency of launches. Consequently, it has led to the rapid developmen…
View article: Determinants and Consequences of Management’s Reporting Materiality Discretion
Determinants and Consequences of Management’s Reporting Materiality Discretion Open
View article: Analytic Costate Initialization from Rough State-Trajectory Estimates
Analytic Costate Initialization from Rough State-Trajectory Estimates Open
View article: Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study
Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study Open
Research within a gynecologic oncology population has lagged behind the uptake in use of medical cannabis for symptom control. This study seeks to evaluate patient experience with prescribed medical cannabis obtained through licensed dispe…
View article: The role of natural clays in the sustainability of landfill liners
The role of natural clays in the sustainability of landfill liners Open
Engineered synthetic liners on their own are not the ideal solution to protect land, water and living beings against landfill leachate pollution. Despite their impermeability, engineered liners are susceptible to fail during installation a…
View article: Virginia Tech Ground Station - Satellite Mission Data Warehouse
Virginia Tech Ground Station - Satellite Mission Data Warehouse Open
Provide centralized mission data management and data warehousing for the Virginia Cubesat Constellation (VCC). Consists of 3 cubesats primarily developed by undergraduates at Virginia Tech (VT), University of Virginia (UVA), and Old Domini…
View article: VT ThickSat: A Passive Deployer Mechanism for a Carbon Fiber Tape Spring in the ThinSat Program
VT ThickSat: A Passive Deployer Mechanism for a Carbon Fiber Tape Spring in the ThinSat Program Open
The passive deployer mechanism will fly on Virginia Tech’s ThinSat mission, VT ThickSat, scheduled to launch along with the resupply mission to the ISS, NG-15. This mission is a proof-of-concept that could lead to similar deployable struct…
View article: VT ThickSat: A Scalable Chassis in the ThinSat Program
VT ThickSat: A Scalable Chassis in the ThinSat Program Open
This paper presents a scalable design of a small satellite chassis for the ThinSat Program. This versatile chassis will fly on Virginia Tech’s ThinSat mission in 2020, VT ThickSat. By incrementing the volume of the satellite chassis, stude…
View article: Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes
Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes Open
Aims: To compare baseline risk factors for type 1 vs. 2 endometrial cancers and analyze these risk factors for association with overall survival and time to recurrence. Methods: Retrospective review of 816 consecutive endometrial cancer ca…